Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Publication year range
1.
J Anim Physiol Anim Nutr (Berl) ; 100(6): 1169-1178, 2016 Dec.
Article in English | MEDLINE | ID: mdl-26825738

ABSTRACT

The objective of the present study was to evaluate a potential of Schizochytrium microalga oil to alleviate possible negative effects of high-fat-high-energy diets. Forty adult male rats (Wistar Albino) were fed 7 weeks the diet containing beef tallow + evaporated sweetened milk (diet T) intended to cause mild obesity and low-grade systemic inflammation. Consequently, the animals were divided into four groups by 10 animals each and fed either the T-diet (control) or the diet containing 6% of safflower oil (S), 6% of fish oil (F) and 6% of Schizochytrium microalga oil (A), respectively, for another 7 weeks. The A-diet decreased (p < 0.05) live weight to 86% and glycaemia to 85% of control, respectively; an effect of the S- and F-diet on these markers was insignificant (p > 0.05). In comparison with control, higher (p < 0.05) deposition of eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in the epididymal adipose tissue (EAT) of the A-rats correlated with increased (p < 0.05) plasma adiponectin concentration, but it was without the effect (p > 0.05) on cellular adiponectin content in the EAT. Higher (p < 0.05) EPA+DHA deposition in the liver of the A-rats correlated with higher expression (149% of control; p < 0.05) of the gene coding for peroxisome proliferator-activated receptor gamma, and with lower expression (82% and 66%; p < 0.05) of the genes coding for adiponectin receptors AdipoR1 and AdipoR2; no relationship to the expression of receptor GPR120 was found. The A-diet did not affect amount of the nuclear fraction of the nuclear factor kappa B in the liver, but increased plasma level of anti-inflammatory cytokine TGF-ß1 (p < 0.05). The presented data agree with results of other in vivo rodent and human studies, but not with literature data regarding in vitro experiments: it can be concluded that the effects of dietary oils on inflammatory markers need further investigation.


Subject(s)
Inflammation/drug therapy , Microalgae/chemistry , Plant Oils/pharmacology , Adiponectin/genetics , Adiponectin/metabolism , Animal Feed/analysis , Animals , Cytokines/genetics , Cytokines/metabolism , Diet/veterinary , Gene Expression Regulation/drug effects , Male , NF-kappa B/genetics , NF-kappa B/metabolism , PPAR gamma/genetics , PPAR gamma/metabolism , Plant Oils/chemistry , Random Allocation , Rats , Rats, Wistar
2.
J Anim Physiol Anim Nutr (Berl) ; 99(2): 308-16, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25040911

ABSTRACT

The purpose of the study was to test the hypothesis that the dietary oils with different content of n-3 polyunsaturated fatty acids (PUFA) eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) affect plasma lipid level in rats in a different degree. The diets with 6% of fish oil (FO) and Schizochytrium microalga oil (SchO; EPA+DHA content in the diets 9.5 + 12.3 and 2.6 + 29.5% of the sum of total fatty acids, respectively) were used; the diet with 6% of safflower oil (high content of n-6 PUFA linoleic acid, 65.5%; EPA+DHA content 0.7 + 0.9%) was used as a control. The difference between FO and SchO was established only in the case of plasma triacylglycerol (TAG) level: plasma TAG of the FO-fed rats did not differ from the control rats (p > 0.05), while SchO decreased (p < 0.05) plasma TAG to 46% of the control. On the other hand, FO and SchO decreased (p < 0.05) total plasma cholesterol (TC) in rats in the same extent, to 73% of the control. Regarding the underlying mechanisms for the TC decrease, both SchO and FO up-regulated hepatic Insig-1 gene (181 and 133% of the control; p < 0.05), which tended (p = 0.15 and p = 0.19 respectively) to decrease the amount of hepatic nSREBP-2 protein (61 and 66% of the control). However, neither SchO nor FO influenced hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase gene expression (p > 0.05); SchO (but not FO) increased (p < 0.05) low-density lipoprotein receptor mRNA in the liver. It was concluded that the decrease of total plasma cholesterol might be caused by an increased cholesterol uptake from plasma into the cells (in the case of SchO), but also by other (in the present study not tested) mechanisms.


Subject(s)
Animal Feed/analysis , Cholesterol/blood , Fish Oils/pharmacology , Microalgae/chemistry , Plant Oils/pharmacology , Animals , Diet , Fatty Acids, Unsaturated/chemistry , Fatty Acids, Unsaturated/metabolism , Fish Oils/chemistry , Gene Expression Regulation/drug effects , Liver/chemistry , Liver/metabolism , Male , Plant Oils/chemistry , Random Allocation , Rats , Rats, Wistar , Sterol Regulatory Element Binding Protein 2/genetics , Sterol Regulatory Element Binding Protein 2/metabolism
3.
Klin Onkol ; 26(4): 239-44, 2013.
Article in Czech | MEDLINE | ID: mdl-23961853

ABSTRACT

Anthracycline cytostatics can be observed at the level of organelles, cells and whole organisms due to their fluorescent properties. Imaging techniques based on detection of fluorescence can be used not only for observation of drug interaction with tumor cells, but also for targeting therapy of tumors with nanoparticles containing anthracycline cytostatics. Doxorubicin and daunorubicin, enclosed in liposomes, as representatives of nanoparticles suitable for targeted therapy, are used in clinical practice. The main advantage of liposomal drugs is to reduce the side effects due to differences in pharmacokinetics and distribution of the drug in the body. Due to the fact that all biological mechanisms of action of anthracycline drugs are not still fully understood, modern imaging techniques offer tool for in vivo studies of these mechanisms.


Subject(s)
Anthracyclines/administration & dosage , Cytostatic Agents/administration & dosage , Doxorubicin/administration & dosage , Microscopy, Fluorescence , Animals , Antibiotics, Antineoplastic , Daunorubicin/administration & dosage , Drug Carriers , Humans , Liposomes , Mice
4.
Neoplasma ; 59(2): 191-201, 2012.
Article in English | MEDLINE | ID: mdl-22248277

ABSTRACT

Current diagnostic techniques are inefficient in distinguishing latent and low-risk forms of prostate cancer from high-risk forms. The present study is focused on determination of putative tumor markers of aggressive high-grade forms of prostate cancer. Potential markers were determined in blood sera of 133 patients (82 cases and 51 controls) and in cell lines (Gleason score 9-derived 22Rv1 and normal tissue derived PNT1A) on mRNA and protein levels. Alpha-methylacyl-CoA racemase (AMACR), metallothionein classes 1A and 2A (MT1A and MT2A) were determined and compared to prostate specific antigen (PSA) levels. On mRNA level, significantly increased expression of MT2A (2.4-fold), PSA (2.6-fold) and AMACR (8.4-fold) and insignificantly (1.9-fold) elevated MT1A in 22Rv1 compared to non-tumor PNT1A were determined. On protein level, significant enhancement of free PSA and total PSA in tumor cell line was evident. AMACR protein was 1.5-fold elevated in tumor line (below the level of significance). Contrary to mRNA, significantly (p = 0.01) reduced level of MT protein in tumor lines was determined. In the case of serum level, significantly enhanced MT level (4.5-fold) in patients' sera was found. No significant changes were observed in the case of AMACR. These findings indicate possible alternative role of MT to PSA prostate cancer marker. In addition, level of AMACR is distinctly higher in the Gleason score 9 in serum of patients and MT shows a descending trend in relation to Gleason score.


Subject(s)
Adenocarcinoma/genetics , Biomarkers, Tumor/genetics , Metallothionein/genetics , Prostate-Specific Antigen/genetics , Prostatic Neoplasms/genetics , Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Adult , Aged , Biomarkers, Tumor/metabolism , Blotting, Western , Case-Control Studies , Humans , Male , Metallothionein/metabolism , Middle Aged , Neoplasm Grading , Prognosis , Prostate-Specific Antigen/metabolism , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , RNA, Messenger/genetics , Racemases and Epimerases/genetics , Racemases and Epimerases/metabolism , Real-Time Polymerase Chain Reaction
5.
Curr Med Chem ; 18(33): 5041-51, 2011.
Article in English | MEDLINE | ID: mdl-22050752

ABSTRACT

Zinc(II) ions contribute to a number of biological processes e.g. DNA synthesis, gene expression, enzymatic catalysis, neurotransmission, and apoptosis. Zinc(II) dysregulation, deficiency and over-supply are connected with various diseases, particularly cancer. 98 % of human body zinc(II) is localized in the intracellular compartment, where zinc(II) is bound with low affinity to metallothionein (MT). Zinc transporters ZIP and ZnT maintain transmembrane transport from/to cells or organelles. Imbalance of their regulation is described in cancers, particularly prostate (down-regulated zinc transporters ZIP1, 2, 3 and ZnT-2) and breast, notably its high-risk variant (up-regulated ZIP6, 7, 10). As a result, intracellular and even blood plasma zinc(II) levels are altered. MT protects cells against oxidative stress, because it cooperates with reduced glutathione (GSH). Recent studies indicate elevated serum level of MT in a number of malignancies, among others in breast, and prostate. MT together with zinc(II) affect apoptosis and proliferation, thus together with its antioxidative effects it may affect cancer. To date, only little is known about the influence of zinc(II) and MT on cancer, while these compounds may play an important role in pathogenesis. This review concludes current data regarding the impact of zinc(II) on the pathogenesis of breast and prostate cancers with potential outlines of new, targeted therapy and prevention. Moreover, blood plasma zinc(II) and MT levels and dietary zinc(II) intake are discussed in relation to breast and prostate cancer risk.


Subject(s)
Breast Neoplasms/pathology , Prostatic Neoplasms/pathology , Zinc/metabolism , Breast Neoplasms/metabolism , Carrier Proteins/metabolism , Female , Humans , Male , Metallothionein/metabolism , Prostatic Neoplasms/metabolism , Sulfhydryl Compounds/chemistry , Zinc/blood
6.
Klin Onkol ; 24(4): 249-55, 2011.
Article in Czech | MEDLINE | ID: mdl-21905614

ABSTRACT

In many developed countries, prostate cancer is the most common male tumour disease. The high incidence and mortality requires early diagnosis, differentiation of aggressive, highly malignant forms from clinically silent forms and understanding of the pathogenesis with its typical metabolic aberrancies (if any) in order to develop new targeted therapies. Prostate cells (including prostate cancer cells) are unique in their relation to zinc ions. Prostate tissue can accumulate these ions in up to tenfold higher concentration than other body cells. These ions influence many cellular processes incl. proliferation, differentiation and apoptosis. Prostate cancer cells lack ability to accumulate zinc. Therefore, zinc ions may be expected to play an important role in the disease pathogenesis, in its propagation and metastatic potential of tumour cells. Intracellular zinc levels are regulated by zinc-binding proteins, especially metallothioneins, and zinc transporters. Zinc level regulation dysfunction has been identified in prostate cancer cells and may thus play an important role in the prostate cancer pathogenesis. Moreover, due to its overproduction by prostate tissue, metallothionein serum levels are elevated and can be used as an important tumour marker.


Subject(s)
Prostatic Neoplasms/physiopathology , Zinc/physiology , Humans , Male , Metallothionein/physiology
7.
Bratisl Lek Listy ; 112(8): 435-40, 2011.
Article in English | MEDLINE | ID: mdl-21863613

ABSTRACT

This review gives a brief summary on clinical applications of MMPs and their determination. Primarily, the activity of MMPs in cancer formation, development and metastasis is discussed. Further, survey on methods including fluorimetric methods, zymographies, Western-blotting, immunocapture assay, enzyme-linked immunosorbent assay, immunocytochemistry and immunohistochemistry, phage display, multiple-enzyme/multiple-reagent system, activity profiling, chronopotentiometric stripping analysis and imaging methods for detection and determination of MMPs follows (Fig. 3, Ref. 100).


Subject(s)
Matrix Metalloproteinases/physiology , Biomarkers/analysis , Humans , Matrix Metalloproteinases/analysis , Matrix Metalloproteinases/chemistry , Neoplasms/diagnosis , Neoplasms/physiopathology
8.
Curr Med Chem ; 17(31): 3751-68, 2010.
Article in English | MEDLINE | ID: mdl-20846107

ABSTRACT

Matrix metalloproteinases (MMPs), also known as matrixins, belong to a group of zinc-dependent proteins, which are thought to play a central role in the breakdown of extracellular matrix. Collagen, elastin, gelatin and casein are major components cleaved by MMPs. The breakdown of these components is essential for many physiological processes such as embryonic development, morphogenesis, reproduction, and tissue resorption and remodelling. MMPs also participate in pathological processes such as arthritis, cancer, cardiovascular and neurological diseases. This review summarizes current knowledge regarding these proteins, their participation in physiological and pathophysiological roles, their involvement in activation and inhibition, and their interactions with other metal-binding proteins including metallothioneins.


Subject(s)
Cardiovascular Diseases/enzymology , Extracellular Matrix/metabolism , Matrix Metalloproteinases/metabolism , Neoplasms/enzymology , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/physiopathology , Cysteine/metabolism , Gene Expression Regulation, Enzymologic , Humans , Matrix Metalloproteinase Inhibitors , Matrix Metalloproteinases/chemistry , Matrix Metalloproteinases/genetics , Neoplasms/drug therapy , Neoplasms/physiopathology , Substrate Specificity , Tissue Inhibitor of Metalloproteinases/metabolism , Zinc Compounds/chemistry , Zinc Compounds/metabolism , Zinc Compounds/pharmacology
9.
Bratisl Lek Listy ; 110(2): 93-7, 2009.
Article in English | MEDLINE | ID: mdl-19408840

ABSTRACT

The latest research outcomes indicate that metallothionein (MT) levels in peripheral blood and serum from cancer patients can provide many interesting information about type or clinical stage of the disease, or response to therapy. MT plays a key role in transport of essential heavy metals, detoxification of toxic metals and protection of cells against oxidation stress. Serum MT levels of cancer patients are three times higher than control patients (0.5 microM). The elevated MT levels in cancer cells are probably related to their increased proliferation and protection against apoptosis. Automated electrochemical detection of MT allows its serial analysis in a very small volume with excellent sensitivity, reliability and reproducibility and therefore it can be considered as a new tool for cancer diagnosis (Fig. 4, Ref. 55). Full Text (Free, PDF) www.bmj.sk.


Subject(s)
Biomarkers, Tumor/blood , Metallothionein/blood , Neoplasms/diagnosis , Electrochemical Techniques , Humans , Metallothionein/physiology , Neoplasms/blood
SELECTION OF CITATIONS
SEARCH DETAIL
...